PARP1 as a prognostic biomarker for human cancers: a meta-analysis.
Yan-Hua HuangSun-Jun YinYuan-Yuan GongZhi-Ran LiQin YangYu-Xin FanTao ZhouRui MengPing WangGong-Hao HePublished in: Biomarkers in medicine (2021)
Aim: A comprehensive meta-analysis was carried out to evaluate the association between high PARP1 expression and clinical outcomes in diverse types of cancers. Materials & methods: The electronic databases for all articles about PARP1 expression and cancers were searched. Additionally, bioinformatics analysis was utilized to validate the results of the meta-analysis. Results: Fifty-two studies with a total of 7140 patients were included in the current meta-analysis. High PARP1 expression was found to be significantly associated with poor overall survival and recurrence in various cancers, which were further strengthened and complemented by the results of bioinformatic analysis. Furthermore, increased PAPR1 expression was also related to clinicopathological features. Conclusion: Our findings confirmed that PARP1 might be a promising biomarker for prognosis in human cancers.
Keyphrases
- systematic review
- poor prognosis
- dna damage
- dna repair
- endothelial cells
- case control
- meta analyses
- binding protein
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- bioinformatics analysis
- prognostic factors
- induced pluripotent stem cells
- peritoneal dialysis
- young adults
- deep learning
- data analysis